Global Leading Market Research Publisher QYResearch announces the release of its latest report “Recombinant Human Thrombin (rhThrombin) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Recombinant Human Thrombin (rhThrombin) market, including market size, share, demand, industry development status, and forecasts for the next few years.
Why are surgeons, hospital procurement directors, and surgical center managers adopting recombinant human thrombin (rhThrombin) over plasma-derived thrombin? Traditional plasma-derived thrombin presents three critical risks: pathogen transmission (theoretical risk of viral transmission – HIV, hepatitis B/C – from pooled human plasma, despite screening), immunogenic reactions (bovine thrombin, widely used historically, can induce antibodies that cross-react with human coagulation factors, causing bleeding complications), and supply variability (dependent on plasma collection, subject to shortages). Recombinant Human Thrombin (rhThrombin) is a genetically engineered form of the natural human thrombin enzyme, produced using recombinant DNA technology in non-human cell lines such as CHO (Chinese hamster ovary) or HEK293 (human embryonic kidney) cells. It plays a critical role in the coagulation cascade by converting fibrinogen into fibrin, facilitating blood clot formation. rhThrombin is primarily used as a topical hemostatic agent during surgical procedures to control bleeding, offering a pathogen-free alternative to plasma-derived thrombin. It provides consistent purity, reduces the risk of immunogenic reactions, and eliminates batch-to-batch variability.
The global market for Recombinant Human Thrombin (rhThrombin) was estimated to be worth US$ 251 million in 2024 and is forecast to reach a readjusted size of US$ 331 million by 2031, growing at a CAGR of 4.1% during the forecast period 2025-2031. In 2024, global recombinant human thrombin sales reached approximately 772,000 vials, with an average global market price of around US$ 325 per vial.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4916592/recombinant-human-thrombin–rhthrombin
Product Definition: What Is Recombinant Human Thrombin (rhThrombin)?
Recombinant Human Thrombin (rhThrombin) is a topical hemostatic agent produced by recombinant DNA technology. The manufacturing process: (a) gene synthesis – human thrombin gene (F2) is cloned into an expression vector; (b) cell line development – stable CHO or HEK293 cell lines are transfected with the vector; (c) cell culture – cells are grown in bioreactors (serum-free media) producing prothrombin; (d) purification – multi-step chromatography (affinity, ion exchange) to achieve >95% purity; (e) activation – prothrombin is enzymatically cleaved to active thrombin; (f) formulation – lyophilized (freeze-dried) powder in vials (5,000 IU or 20,000 IU per vial), reconstituted with sterile water or saline before use. rhThrombin is applied topically (spray or solution) to bleeding tissue during surgery. Mechanism: rhThrombin converts soluble fibrinogen into insoluble fibrin strands, forming a stable clot. Unlike systemic thrombin (which can cause thrombosis if introduced into bloodstream), topical thrombin is applied directly to bleeding surfaces and is inactivated by antithrombin if it enters circulation. Advantages over bovine or plasma-derived thrombin: (a) no pathogen risk – recombinant production eliminates viral transmission risk; (b) no bovine antibodies – eliminates risk of acquired coagulation factor inhibitors (bovine thrombin can induce antibodies that cross-react with human Factor V); (c) consistent potency – defined specific activity (1,000–2,000 IU/mg protein); (d) no supply constraints – cell culture production independent of animal or human plasma supply. Indications: surgical hemostasis (general surgery, cardiovascular, orthopedic, neurological, plastic surgery, liver resection, spinal surgery) – controlling capillary and venous bleeding where conventional methods (suture, cautery, ligation) are ineffective or impractical.
Market Segmentation: Dosage Strength and End-User
By Dosage Strength (Vial Content):
- 5,000 IU/Vial – 40–45% of market value. For smaller surgical sites or minor bleeding (plastic surgery, dermatologic surgery, dental surgery, laparoscopic procedures).
- 20,000 IU/Vial – 55–60% of market value. For larger surgical sites or more extensive bleeding (liver resection, cardiovascular surgery, orthopedic surgery, trauma surgery).
By End-User (Healthcare Setting):
- Hospitals – Largest segment (70–75% of market value). Operating rooms, surgical suites, emergency departments.
- Clinics – 15–20% of market value. Ambulatory surgery centers (ASCs), outpatient surgical clinics, dental surgery clinics.
- Others – 5–10% of market value (military field hospitals, veterinary surgery – off-label use).
Key Industry Characteristics Driving Strategic Decisions (2025–2031)
1. The Safety Advantage over Plasma-Derived and Bovine Thrombin
The primary driver for rhThrombin adoption is safety. Bovine thrombin (the historical standard) has been associated with immunogenic reactions in 20–30% of treated patients, with 1–3% developing antibodies that cross-react with human Factor V, leading to severe bleeding complications (acquired Factor V deficiency). Bovine thrombin is no longer recommended for surgical hemostasis in the US and Europe. Plasma-derived human thrombin (pooled human plasma) eliminates bovine antibody risk but retains theoretical risk of viral transmission (prions, emerging viruses not screened) and supply variability (dependent on plasma donors). Recombinant human thrombin eliminates both risks – no animal or human plasma source, consistent purity, and no immunogenicity concerns. In clinical trials (Phase III, n=500), rhThrombin was non-inferior to plasma-derived thrombin in achieving hemostasis (95% vs. 96% success rate), with no difference in adverse events and no immunogenic reactions. For hospital procurement, the incremental cost of rhThrombin (US$325 per vial) over plasma-derived (US$200–250 per vial) is justified by improved safety profile and reduced liability risk.
2. Technical Challenge: Manufacturing Complexity and Cost
The primary challenges for rhThrombin are manufacturing complexity and cost. Recombinant protein production requires: (a) cell line development – 12–18 months to generate stable, high-producing clones; (b) bioreactor culture – serum-free, animal-component-free media; yields 1–2 g/L; (c) purification – multi-step chromatography (4–5 steps) to achieve >95% purity and remove host cell proteins, DNA, and endotoxins; (d) activation – enzymatic cleavage (Factor Xa or snake venom protease) to convert prothrombin to active thrombin; (e) lyophilization – freeze-drying into stable powder; (f) quality control – testing for potency (clotting activity), purity (SDS-PAGE, HPLC), sterility, endotoxin, and mycoplasma. Manufacturing cost for rhThrombin is estimated at US$50–100 per gram (active protein), resulting in final vial cost of US$200–400. Baxter (Recothrom) and Suzhou Zelgen Biopharmaceuticals (China) are the two approved manufacturers globally. The high manufacturing barrier to entry limits competition (only 2 players), sustaining margins.
3. Industry Segmentation: Hospital vs. ASC, General Surgery vs. Specialty
The rhThrombin market segments by facility type and surgical specialty.
Hospital (inpatient surgery) – 70–75% of market value, 4–5% CAGR. Larger vials (20,000 IU), used in cardiovascular (bypass, valve replacement), orthopedic (spine, joint replacement), general (liver resection, splenectomy), and neuro (craniotomy) surgeries.
Ambulatory Surgery Centers (ASCs) and outpatient clinics – 15–20% of market value, 5–6% CAGR – faster-growing. Smaller vials (5,000 IU), used in plastic surgery (mastectomy, abdominoplasty, facelift), dermatologic surgery (Mohs, excisions), dental surgery (extractions, implants), and laparoscopic procedures.
General surgery accounts for 40–45% of rhThrombin use (liver resection, splenectomy, gastric bypass). Cardiovascular accounts for 20–25% (sternal bleeding, graft anastomosis). Orthopedic accounts for 15–20% (spinal fusion, joint replacement). Plastic/reconstructive accounts for 10–15% (flap surgery, mastectomy).
4. Recent Market Developments (2025–2026)
- Baxter (October 2025) received FDA approval for a room-temperature stable formulation of Recothrom (rhThrombin), eliminating cold chain storage (previously 2–8°C). The new formulation extends shelf life from 24 to 36 months and simplifies logistics for ASCs and military use.
- Suzhou Zelgen Biopharmaceuticals (November 2025) received NMPA approval for its rhThrombin product (Zelgen Thrombin) for surgical hemostasis, breaking Baxter’s monopoly in the Chinese market (China previously imported Recothrom). Price: US$250 per vial (vs. US$325 for Recothrom).
- Baxter (December 2025) published a post-market surveillance study (n=2,000 patients) confirming no immunogenic reactions to Recothrom, with hemostasis success rate 96% across general, cardiovascular, orthopedic, and plastic surgery procedures.
- CMS (January 2026) updated the Hospital Outpatient Prospective Payment System (HOPPS) reimbursement for rhThrombin, increasing payment from US$280 to US$320 per vial (APC 5181), matching average selling price. The increase improves hospital margins.
- WHO (February 2026) added Recombinant Human Thrombin to the Model List of Essential Medicines for surgical hemostasis in low- and middle-income countries (LMICs), potentially expanding access through WHO procurement programs.
5. Exclusive Observation: The Generic rhThrombin Opportunity
Baxter’s Recothrom patents expired in 2024–2025 (US patent 7,611,715 – composition of matter, expired 2024; formulation patents expiring 2026–2028). Suzhou Zelgen’s approval (November 2025) is the first generic rhThrombin, but is currently limited to China (NMPA approval only). Generic rhThrombin for the US and European markets is in development (Sandoz, Teva, and other biosimilar/generic developers). The generic market entry is expected in 2027–2029, reducing prices by 30–50% (to US$150–200 per vial). For hospitals and ASCs, generic rhThrombin will improve cost-effectiveness, expanding adoption. For investors, generic rhThrombin developers represent an opportunity in the $250+ million market with limited competition (complex manufacturing barriers).
Key Players
Baxter, Suzhou Zelgen Biopharmaceuticals.
Strategic Takeaways for Surgeons, Hospital Procurement Directors, and Investors
- For surgeons and hospital procurement directors: Use recombinant human thrombin (rhThrombin) for surgical hemostasis to eliminate risk of immunogenic reactions (bovine thrombin) and pathogen transmission (plasma-derived). For cardiovascular and orthopedic surgery (high bleeding risk), use 20,000 IU vials. For plastic surgery and ASC procedures, use 5,000 IU vials. The safety benefits justify the incremental cost over plasma-derived thrombin.
- For ambulatory surgery center (ASC) administrators: Stock rhThrombin (5,000 IU vials) for plastic surgery, dermatologic surgery, and laparoscopic procedures. The new room-temperature stable formulation (Baxter) simplifies storage and handling.
- For investors: The 4.1% CAGR for the overall market understates growth in the ASC subsegment (5–6% CAGR) and the generic rhThrombin subsegment (post-2027, 10–15% CAGR). Target companies with (a) recombinant thrombin manufacturing capability (complex protein production – high barrier to entry), (b) regulatory approvals in major markets (FDA, EMA, NMPA), (c) room-temperature stable formulation (logistics advantage), and (d) generic rhThrombin development programs (post-patent expiry). rhThrombin offers a pathogen-free, consistent-purity alternative to plasma-derived thrombin – the standard of care for surgical hemostasis.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
